prostate%20cancer
PROSTATE CANCER

Prostate cancer is the cancer that occurs in the male's prostate.

It is the most common cancer in men >50 years of age.

Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.

Prostate Cancer Drug Information

Drug Information

Indication: Osteoporosis in postmenopausal women at increased risk of fracture. Increases bone mineral density & reduc...

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: Locally advanced or metastatic prostate cancer. Genital & extragenital stage I-IV endometriosis. Precociou...

Indication: Palliative treatment of hormone-dependent advanced prostate cancer. High-risk localized & locally advanced...

Indication: Non-metastatic castration-resistant prostate cancer in adult men who are at high risk of developing metastatic...

Indication: Adult men w/ metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after ...

Indication: In combination w/ prednisone or prednisolone for metastatic castration resistant prostate cancer (mCRPC) in ad...

Indication: In combination w/ prednisone or prednisolone for metastatic castration resistant prostate cancer in adult men ...

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

1  /  6
Editor's Recommendations
Most Read Articles
Stephen Padilla, 06 Aug 2020
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
06 Aug 2020
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.